Sun Yat-sen University: Carcinoma, Hepatocellular trials

The registry lists 175 Carcinoma, Hepatocellular studies with Sun Yat-sen University as lead sponsor. 52 are open to participants now and 1 have results posted.

Phase 1 3Phase 2 55Phase 3 54Phase 4 18No phase 50(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Beyond Milan Criteria BCLC Stage A/B Hepatocellular Carcinoma Who Underwent HepatectomyStatus unknownNCT03851913Phase 3
• The Efficacy of Transarterial Chemoinfusion (TAI) Combine Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC)Status unknownNCT03851887Phase 2
• HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCCStatus unknownNCT03812783Phase 2
• Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCCStatus unknownNCT03812770Phase 2
• HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCCWithdrawnNCT03803254Phase 2
• Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven CriteriaWithdrawnNCT03791918Phase 3
• TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCCWithdrawnNCT03782831Phase 2
• HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCCWithdrawnNCT03780634Phase 2
• HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-BStatus unknownNCT03780049Phase 3
• the Effect of Different Oxaliplatin Dose in Transarterial Infusion (TAI) in Unresectable Hepatocellular CarcinomaStatus unknownNCT03777475Not applicable
• HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCCStatus unknownNCT03775395Phase 3
• Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCCWithdrawnNCT03746249Phase 2
• Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCCWithdrawnNCT03744247Phase 3
• Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACEWithdrawnNCT03722498Phase 2
• TACE-HAIC vs. HAIC for Potentially Resectable HCCStatus unknownNCT03591705Not applicable
• Neoadjuvant HAIC for Resectable Hepatocellular Carcinoma Beyond Milan CriteriaStatus unknownNCT03469479Phase 3
• HAIC of FOLFOX vs. HAIC of OXA for Advanced HCCStatus unknownNCT03468231Phase 3
• The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.Status unknownNCT03192644Phase 3
• The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.Status unknownNCT03192618Phase 3
• Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular CarcinomaCompletedNCT03164382Phase 3
• HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/BCompletedNCT03048123Phase 2
• The Impact on Therapeutic Effect and Tolerance of Treatment for Patients With Hepatocellular Carcinoma in Transcatheter Arterial Chemoembolization (TACE) of Dexamethasone Application: A Random, Double-blind, Controlled, Clinical Trial.Status unknownNCT02987907Phase 3
• Phase II Study of HAIC Using Cisplatin,Leucovorin and 5-FluorouracilStatus unknownNCT02987699Phase 2
• Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular CarcinomaCompletedNCT02981498Phase 2
• HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.CompletedNCT02973685Phase 3
• RCT of TAE Simultaneously Combined Thermal Ablation for Large Hepatocellular CarcinomaStatus unknownNCT02964260Not applicable
• Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical TrailCompletedNCT02961998Phase 4
• Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical ResectionTerminatedNCT02867280Phase 3
• HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCCCompletedNCT02856126Phase 3
• A Novel Laparoscopic Hepatectomy Posture, Left Lateral Position Plus Jackknife PositionCompletedNCT02809287
• Adjuvant TACE to Reduce the HCC Recurrence After ResectionCompletedNCT02788526Phase 3
• Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCCCompletedNCT02774187Phase 3
• Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular CarcinomaStatus unknownNCT02755311Phase 3
• Adjuvant Chemotherapy With FOLFOX in HCC Patients After ResectionStatus unknownNCT02738697Phase 3
• Resection+Highly Purified CTL Versus Resection Alone for HCCStatus unknownNCT02709070Phase 3
• Efficacy Analysis of Complete Laparoscopic Resection of Recurrent Hepatocellular CarcinomaCompletedNCT02613156
• Preventive Effects of Parecoxib on Postoperative Complications in Hepatocellular Carcinoma Patients Undergoing Hepatic Transcatheter Arterial ChemoembolizationCompletedNCT02552745
• Laparoscopic Surgery Versus Radiofrequency Ablation for Recurrent HCCStatus unknownNCT02535117Phase 4
• HR Combined With FOLFOX4 for HCC With PVTTStatus unknownNCT02452853Phase 2
• RFA Combined With Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) for Recurrent HCCStatus unknownNCT02426450Phase 2
• The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled TrialTerminatedNCT02220088Phase 2/3
• Hepatectomy Versus Chemoembolization for Resectable Hepatocellular Carcinoma Beyond Milan CriteriaStatus unknownNCT02138981Phase 4
• A Simple Prognostic Scoring System for Patients Receiving Transarterial Chemoembolization for Hepatocellular CarcinomaCompletedNCT02061956
• Hepatectomy Versus Hepatectomy With Lymphadenectomy in Hepatocellular CarcinomaCompletedNCT02031952Not applicable
• Preoperative Transarterial Chemoembolization for Resectable HCC With Portal Venous InvasionCompletedNCT01952353Phase 4
• Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA ReplicationStatus unknownNCT01894269Phase 4
• TACE Plus Recombinant Human Adenovirus for Hepatocellular CarcinomaStatus unknownNCT01869088Phase 3
• Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular CarcinomaCompletedNCT01833299Phase 3
• TACE+RFA Versus Re-resection for Recurrent Small Hepatocellular CarcinomaStatus unknownNCT01833286Phase 3
• CIK Treatment for HCC Patient Underwent Radical ResectionCompletedNCT01749865Phase 3
• Optimal Treatment on Hepatocellular Carcinoma (HCC) With Cirrhotic Portal HypertensionCompletedNCT01642446Not applicable
• Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous ThrombusTerminatedNCT01600196Phase 4
• Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular CarcinomaStatus unknownNCT01570166Not applicable
• Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan CriteriaStatus unknownNCT01570075Phase 4
• A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid TumorsStatus unknownNCT01462903Phase 1
• Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular CarcinomaStatus unknownNCT01415063Phase 4
• Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)CompletedNCT01409499Phase 4
• Radiofrequency Ablation Versus Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cmStatus unknownNCT01351194Phase 4
• Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor ThrombosisStatus unknownNCT01350206Phase 4
• Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular CarcinomaCompletedNCT01259414Phase 3
• Chemoembolization With or Without Mixing the Chemotherapy With Lipiodol for Unresectable HCCCompletedNCT01229839Phase 3
• Multi-pronged Ethanol Ablation and Radiofrequency Ablation of Early-stage Hepatocellular CarcinomaCompletedNCT00844454Not applicable
• Diagnosis of Hepatic Tumors in Cirrhosis: Prospective Validation of the Noninvasive Diagnostic Criteria for Hepatocellular CarcinomaStatus unknownNCT00842647
• Study of Cytokine-induced Killer Cell (CIK) Treatment in Patients After Resection of Liver CancerCompletedNCT00769106Phase 3
• Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular CarcinomaStatus unknownNCT00768157Phase 4
• Low-Dose Thalidomide as Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular CarcinomaStatus unknownNCT00728078Phase 2/3
• The Risk of Exacerbation of Chronic Hepatitis B After Percutaneous Radiofrequency Ablation of Hepatocellular CarcinomaStatus unknownNCT00720668
• Hepatectomy With or Without Transcatheter Arterial Chemoembolization for Stage IIIA Hepatocellular CarcinomaCompletedNCT00652587Phase 3
• Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor ThrombosisCompletedNCT00646100Phase 4
• Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular CarcinomaStatus unknownNCT00557024Phase 4
• TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular CarcinomaStatus unknownNCT00556803Phase 4
• Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular CarcinomaStatus unknownNCT00555334Phase 4
• Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular CarcinomaStatus unknownNCT00554905Phase 4
• Multimodality Therapy for Palliative Resectable Hepatocellular Carcinoma With Intrahepatic Vessels InvasionStatus unknownNCT00501813Phase 3
• Different Regimens of Transarterial Chemoembolization for Hepatocellular CarcinomaCompletedNCT00493402Phase 3